Investigating pain after liver transplantation with FK506 therapy
Investigation of Pain Incidence After FK506 Immunosuppressive Therapy in Liver Transplantation Patients
The Second Hospital of Tangshan · NCT04559048
This study looks at how FK506 treatment affects pain levels in people who have received a liver transplant.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The Second Hospital of Tangshan (other) |
| Locations | 1 site (Tangshan, Hebei) |
| Trial ID | NCT04559048 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the incidence and intensity of pain in liver transplantation patients who received FK506 (tacrolimus) as part of their immunosuppressive therapy. The study will analyze data from patients who underwent liver transplants between September 2011 and May 2018, comparing those treated with FK506 to those who were not. By examining the relationship between FK506 treatment and pain outcomes, the study seeks to provide objective clinical evidence regarding pain associated with this immunosuppressant. The findings could enhance understanding of pain management in liver transplant recipients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have undergone liver transplantation for end-stage liver disease.
Not a fit: Patients with liver cancer, acute liver failure, or chronic pain conditions such as fibromyalgia or osteoarthritis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved pain management strategies for liver transplant patients receiving FK506 therapy.
How similar studies have performed: While FK506 is a well-established immunosuppressant, this specific investigation into its association with pain incidence in liver transplant patients is novel and has not been extensively studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. had liver transplantation for end-stage liver disease 2. was ≥18 years of age at the time of liver transplantation - Exclusion Criteria: 1. liver cancer 2. acute (fulminant) liver failure 3. multiorgan transplant 4. chronic postsurgical pain 5. fibromyalgia, osteoarthritis, low back pain and inflammatory pain of any origin 6. peripheral and central neuropathic pain of any origin 7. chronic secondary visceral pain 8. chronic cancer-related pain that is due to cancer or its treatment -
Where this trial is running
Tangshan, Hebei
- The Second Hospital of Tangshan — Tangshan, Hebei, China (RECRUITING)
Study contacts
- Study coordinator: Gang Zhao, M.D.
- Email: tseyyjk@163.com
- Phone: +8603152058037
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Chronic Pain, Liver Transplantation, FK506